Meriam KABBAJ is a pharmacist by training (University of Geneva) and received her Master's and Ph.D. in Pharmaceutical Sciences from the University of Montreal.
She acquired clinical drug development experience and was exposed to quality assurance and regulatory affairs in a leading Contract Research Organization (Celerion, formerly MDS Pharma Sciences) specialized in applied translational medicine, where she held many key operational and leadership positions. After a 10-year-deep dive into the pharmaceutical industry, she co-founded Versantis where she successfully led the development of VS-01 from an academic prototype to a clinical lead compound and supported the fundraising activities.
As a result of the acquisition of Versantis by GENFIT in September 2022, Meriam joined the Executive Committee as Chief Technology Officer in charge of CMC, Analytical Chemistry, and Non-Clinical Development activities.
Sign up to view 1 direct report
Get started